Acute oesophageal necrosis in multiple endocrine neoplasia type 1: an undescribed complication

  1. Sumona Bhattacharya 1,
  2. Jenny E Blau 2 and
  3. Christopher Koh 3
  1. 1 Digestive Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
  2. 2 Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
  3. 3 Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
  1. Correspondence to Dr Sumona Bhattacharya; sumona.bhattacharya@nih.gov

Publication history

Accepted:11 Dec 2020
First published:07 Jan 2021
Online issue publication:07 Jan 2021

Case reports

Case reports are not necessarily evidence-based in the same way that the other content on BMJ Best Practice is. They should not be relied on to guide clinical practice. Please check the date of publication.

Abstract

Acute oesophageal necrosis (AEN) is a rare entity that most commonly presents as upper gastrointestinal bleeding. Complex pathophysiology may include oesophageal ischaemia as well as reflux of acidic gastric contents causing oesophageal mucosal injury. Management is supportive and directed at underlying comorbidities however prognosis is poor with complications such as oesophageal perforation, stricture and stenosis. Here we present the case of a 56-year-old man with multiple endocrine neoplasia type 1 (MEN1) and gastro-oesophageal reflux disease who developed AEN as a result of undiagnosed Zollinger-Ellison syndrome (ZES), duodenal ulcer-induced obstruction and hypotension from new-onset atrial fibrillation. AEN as the presentation of MEN1-associated ZES is an unusual presentation of this disease which clinicians, particularly endocrinologists and endoscopists, should be aware of.

Background

Acute oesophageal necrosis (AEN), also known as black oesophagus, is a rare disorder which most commonly presents as upper gastrointestinal bleeding.1–4 Other presenting symptoms include nausea, vomiting, dysphagia and epigastric abdominal pain.1 4 The pathophysiology of AEN is complex and includes multiple variables such as hypotension, which causes ischaemic injury to the oesophagus, and oesophageal mucosal injury, which can result from gastric acid.1 2 4 For example, gastric outlet obstruction causes the reflux of gastric acid reflux backwards into the oesophagus and, as such, has been implicated in cases of AEN.5 Oesophageal infections can also contribute to the development of AEN.1

Each third of the oesophagus has a unique vascular supply.2 The distal oesophagus is the most prone to ischaemic injury as its vascular supply is the least robust.2 4 The vascular supply of the stomach, in contrast, is not as vulnerable therefore the extent of mucosal necrosis does not extend distally past the gastro-oesophageal junction.4 6 Histological analysis from affected tissue demonstrates inflammation and necrosis, with the depth of necrosis proportional to the degree of injury.6

There are multiple known risk factors for the development of AEN including male sex, elderly age and certain chronic medical conditions such as diabetes mellitus, malnutrition, renal insufficiency and malignancy.1 2 4 Here we present an atypical and severe case of acute oesophageal necrosis in a patient with multiple endocrine neoplasia type 1 (MEN1), which is a rare presentation of Zollinger-Ellison syndrome (ZES).

Case presentation

A 56-year-old man with MEN1, complicated by hyperparathyroidism and multiple pancreatic neuroendocrine tumours, and gastro-oesophageal reflux disease (GORD) on chronic proton pump inhibitor (PPI) therapy presented for an elective right lower lobectomy and thymectomy for lung and presumed thymic neuroendocrine tumours (NETs). His home medications were omeprazole 40 mg once daily and vitamin D 4000 IU once daily. He had multiple family members with MEN1 including a maternal aunt with ZES. He denied any tobacco use and denied regular heavy alcohol use.

The operation was uncomplicated however he experienced significantly postoperative pain. His pain management regimen included regularly scheduled intravenous ketorolac. On postoperative day 5, he began to report progressively worsening nausea and GORD. These symptoms were so severe that they interfered with his sleep. The following day, his symptoms progressed to include abdominal pain and distention. He then developed new-onset atrial fibrillation with hypotension.

Laboratory examination demonstrated a haemoglobin decline from 9.4 g/dL earlier that morning to 6.2 g/dL. Creatinine was 1.21 mg/dL and blood urea nitrogen was elevated at 62 mg/dL. Liver function panel was within normal limits. Lactate was elevated at 2.3 mmol/L.

He denied any overt bleeding including no vomiting, melena or haematochezia. He was transferred to the intensive care unit (ICU). In the ICU, a nasogastric tube was placed which put out 700 mL of dark red blood; after this, he reported that his abdominal distention and pain were mildly improved. He was given 3 L of normal saline and intravenous PPI therapy (80 mg intravenous bolus of pantoprazole followed by 8 mg/hour continuous infusion) as well as transfused packed red blood cells. Gastroenterology was consulted emergently.

On our exam, the patient was still in significant distress due to abdominal pain. He was febrile at 101.3 °F, tachycardic with heart rate in the 130s and with persistently low-normal blood pressures despite volume resuscitation. His abdomen was distended and tender but without rebound.

Investigations

An emergent upper endoscopy was performed at bedside which demonstrated circumferential black oesophageal mucosa extending proximally from the gastro-oesophageal junction (figure 1), consistent with acute oesophageal necrosis. His gastric mucosa was noted to appear pale. An adherent obstructing clot in the duodenal bulb (figure 2) was not able to be traversed (Forrest score classification IIB), conferring the patient a Rockall score of 7 (associated with 43.8% risk of rebleeding and 27% mortality).

Figure 1

Endoscopic image of oesophageal necrosis, with nasogastric tube in view.

Figure 2

Endoscopic image of duodenal clot, view from within the pyloric channel.

Differential diagnosis

The differential diagnosis of the patient’s acute oesophageal necrosis included hypotension-induced ischaemia (caused by blood loss from the duodenal ulcer, atrial fibrillation and/or arterial occlusion), gastric acid reflux into the oesophagus and/or a postoperative oesophageal infection given his recent thoracic surgery.

Treatment

A CT-angiogram of the abdomen/pelvis was performed which showed patent abdominal vasculature and a few small pockets of free air, which was concerning for a perforated ulcer. Given the phase timing used for this contrast study to identify vessel patency, it was inadequate to visualise known pancreatic lesions. The patient stabilised with conservative therapy consisting of nil-per-os (NPO) diet restriction and continuous intravenous PPI therapy. He was also given prophylactic antimicrobial therapy with meropenem and micafungin. Due to differing medical opinions, the decision was made to repeat the endoscopy in order to re-assess the duodenal ulcer and plan for definitive treatment if necessary.

Outcome and follow-up

A repeat upper endoscopy 36 hours later, performed in the operating room given the high risks of the procedure, demonstrated healing oesophageal mucosa with exudates (figure 3) and normal gastric mucosa. The duodenal clot was able to be traversed during this endoscopy and the second portion of the duodenum was able to be examined, however it was found to contain extensive necrotic mucosa. Due to this finding, the patient was taken for emergency exploratory laparotomy which confirmed the presence of duodenal necrosis as well as revealed a perforated duodenal ulcer (figure 4) eroding into the gastroduodenal artery. A pancreaticoduodenectomy was performed given areas of the duodenum were ischaemic and necrosed beyond primary repair. On pathological examination, the duodenum contained microscopic foci of neuroendocrine tumour consistent with gastrinoma. Fortunately, the patient recovered and was able to be discharged home.

Figure 3

Endoscopic image of healing oesophageal mucosa with exudates.

Figure 4

Resected surgical specimen showing perforated duodenal ulcer.

Discussion

We hypothesise that the development of acute oesophageal necrosis in our patient was a combination of multiple precipitating factors. First, his duodenal ulcer was likely triggered by the regular doses of non-steroidal anti-inflammatory drugs he was receiving postoperatively for pain management, coupled with uncontrolled gastric acid output due to previously undiagnosed ZES. Oesophageal ischaemia was caused by the blood loss from his duodenal ulcer as well as the atrial fibrillation-induced hypotension. Finally, the duodenal ulcer also caused a duodenal obstruction (seen during his first endoscopy) which may have caused reflux of gastric acid into the oesophagus, further causing oesophageal injury. Other cases of AEN have been documented with concomitant duodenal ulcer or duodenal pathology.1 4

Gastrinomas are one of the many types of NETs that may develop as part of the MEN1 syndrome, but our patient did not carry a diagnosis of ZES prior to this event.7 Around 80% of cases of ZES are sporadic and not associated with MEN1.7 Our patient did report chronic GORD prior to this event however his gastrin level prior to this event was 351 pg/mL, well within the range known to be caused by chronic PPI use.8 He had never previously undergone upper endoscopy at our institution. Furthermore, his radiography prior to this event, including Gallium-68 Dotatate and CT imaging, did not show any evidence of duodenal NETs, thickened gastric folds or any other findings specific to ZES. He did have multiple pancreatic NETs seen on imaging however patients with MEN1 may develop multiple different types of pancreatic NETs, including non-functioning pancreatic NETs.7 Foci of microscopic gastrinoma were found in his resected surgical specimen and a repeat gastrin measured after his pancreaticoduodenectomy was <10 pg/mL, altogether suggesting a diagnosis of ZES. AEN as the initial presentation of ZES has been reported in the literature,3 however the report of AEN in a patient with MEN1 or MEN1-associated ZES is not recognised and has not been reported. Clinicians should be aware of the association between MEN1 and AEN as a cause of acute upper gastrointestinal pain with a potential for bleeding and death.

Management of oesophageal necrosis is supportive with NPO diet restriction, PPI and antibiotics, as well as management directed at specific underlying comorbidities.1–4 Potential complications include oesophageal stricture and/or stenosis, and oesophageal perforation.2–4 The prognosis of AEN is poor, with mortality in various case series ranging from 12.5% to 50%, although not all mortality was directly attributable to AEN.1 3 4 Fortunately, our patient recovered and is doing well today.

Learning points

  • Acute oesophageal necrosis is a rare disease and most commonly presents with upper gastrointestinal bleeding.

  • Zollinger-Ellison syndrome should be suspected in patients with multiple endocrine neoplasia type 1.

  • This case report demonstrates the first known presentation of acute oesophageal necrosis in a patient with multiple endocrine neoplasia type 1.

  • The major complications of peptic ulcers include bleeding, perforation and obstruction.

Footnotes

  • Contributors SB provided patient care and drafted the manuscript. JEB provided patient care and edited the manuscript. CK provided patient care, edited the manuscript and supervised this project.

  • Funding This study was funded by National Institute of Diabetes and Digestive and Kidney Diseases.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

References

Use of this content is subject to our disclaimer